Advanced Filters
noise

neoplasms Clinical Trials

A listing of neoplasms medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 14,282 clinical trials
J Jing Yan

Tislelizumab Combined APF Chemotherapy in the Treatment of Locally Advanced Head and Neck Tumors

The goal of this clinical trial is to test in describe participant population. The main questions it aims to answer are: evaluate the efficacy and safety of tislelizumab combined with APF sequential surgery or radical concurrent chemoradiotherapy in the treatment of locally advanced head and neck tumors. the exploration of …

18 - 75 years of age All Phase 2

Metabolic Characteristics of Brain Tumors Using Hyperpolarized Carbon-13 Magnetic Resonance Spectroscopic Imaging (MRSI)

This is a non-randomized, purely observational, feasibility study to detect metabolic changes in patients with brain malignancy using a novel hyperpolarized \[1-13C\]pyruvate MRSI.

18 - 70 years of age All Phase N/A
J Jin Li, PHD

A Phase I Study of SIM0686 in Participants With Locally Advanced/Metastatic Solid Tumors

This is an open-label, multicenter phase 1 study to evaluate the safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0686 in Adult Participants with Locally Advanced/Metastatic Solid Tumors

18 years of age All Phase 1
X Xiujuan Qu

A Study of GFH375 in Patients With Advanced Solid Tumors With KRAS G12D Mutations

This is a multicenter, open-label, phase I/II study to explore the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of GFH375 in patients with advanced solid tumors harboring a KRAS G12D mutation.

18 - 75 years of age All Phase 1/2

A Study of HRS-4642 in Combination With Antineoplastic Agents in Advanced Solid Tumors

To evaluate the safety and preliminary efficacy of HRS-4642 in combination with antineoplastic agents in subjects with advanced solid tumors with KRAS G12D mutations, and to determine the maximum tolerated dose (MTD) and the recommended Phase II dose (RP2D).

18 - 75 years of age All Phase 1/2

A Trial of SHR-A2102 With or Without Antitumor Therapy in Advanced Solid Tumors

The study is being conducted to evaluate the safety, tolerability and efficacy of SHR-A2102 for injection with or without Antitumor Therapy in Advanced Solid Tumors. To explore the reasonable dosage of SHR-A2102 for Advanced Solid Tumors.

18 years of age All Phase 1/2

Phase III Clinical Study of VC004 in Patients With Localized Advanced/ Metastatic Solid Tumors

This Study is a single arm, open label, multicenter phase III clinical trial to evaluate the safety and efficacy of VC004 in patients with locally advanced/metastatic solid tumors.

12 years of age All Phase 3

A Study of BL-M05D1 in Patients With Locally Advanced or Metastatic Solid Tumors

This study is an open-label, multicenter, dose-escalation, and extended-enrollment nonrandomized phase I study to evaluate the safety, tolerability, pharmacokinetic characteristics, and preliminary efficacy of BL-M05D1 in patients with locally advanced or metastatic solid tumors.

18 - 75 years of age All Phase 1

A Study to Investigate ANS014004 in Participants With Locally Advanced or Metastatic Solid Tumors

This is a Phase 1, first-in-human, open-label, multi-center study with the aim of exploring the safety, tolerability, PK, and preliminary anti-tumor activity of ANS014004 as a single agent in participants with locally advanced or metastatic solid tumors.

18 years of age All Phase 1
Y Yunyan Guo

A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.

This study will evaluate the safety, tolerability, and preliminary efficacy of EIK1004 (IMP1707) in participants with recurrent advanced/metastatic breast cancer, ovarian cancer, metastatic castrate resistant prostate cancer (mCRPC) and pancreatic cancer with deleterious/suspected deleterious mutations of select homologous recombination repair (HRR) genes. Condition or disease Intervention/treatment Phase Advanced Solid Tumors …

18 - 89 years of age All Phase 1/2

Simplify language using AI